MedDataX Logo

Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting

NCT ID: NCT04799990

Last Updated: 2022-12-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2021-06-23

Study Completion Date

2022-03-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study is not recruiting and using secondary data sources only

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study is not recruiting and using secondary data sources only

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Risankizumab

Participants will receive risankizumab as prescribed by their physician.

Risankizumab

Intervention Type DRUG

Subcutaneous Injection

Comparator Group 1

Participants will receive biologics other than interleukin (IL)-23 antagonists as prescribed by their physician.

Comparator 1

Intervention Type BIOLOGICAL

Subcutaneous or Intravenous Injection

Comparator Group 2

Participants will receive non-biologic systemic small molecules as prescribed by their physician.

Comparator 2

Intervention Type DRUG

Oral, Opthalmic, Subcutaneous or Intravenous Injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Risankizumab

Subcutaneous Injection

Intervention Type DRUG

Comparator 1

Subcutaneous or Intravenous Injection

Intervention Type BIOLOGICAL

Comparator 2

Oral, Opthalmic, Subcutaneous or Intravenous Injection

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Skyrizi

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Study is not recruiting and using secondary data sources only
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AbbVie

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ABBVIE INC.

Role: STUDY_DIRECTOR

AbbVie

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P16-772

Identifier Type: -

Identifier Source: org_study_id